-
Retatrutide and the Grey Market: Buyer Beware
This should go without saying, but the internet can be both an incredible resource and an extremely dangerous place for health and wellness information. At a time when obesity rates are soaring, mental and emotional stress are at an all-time high, and access to reputable healthcare can feel nearly impossible, many people are turning online in search of solutions. Unfortunately, that desperation leaves individuals vulnerable to the predatory promises of the wellness industry. The latest example is the buzz around retatrutide; or “Reta,” as it’s trending on TikTok. Like candy offered from the back of a van, it’s tempting, accessible,…
-
How GLP-1s Are Reshaping Consumer Behavior
It’s been about a month since FNCE 2025 in Nashville, and I’m still sifting through my notes and revisiting the sessions I loved. One that stood out was the panel “The GLP-1 Effect: Understanding Consumer Behavior Shifts and Their Impact on Food, Nutrition, and Innovation.” The sheer scale of GLP-1 adoption and the depth of the data presented were striking. What made the session even more compelling was its interdisciplinary perspective, bringing together insights from industry leaders, physicians, RDs, and AI-generated consumer modeling. GLP-1 medications are reshaping metabolic health, culture, consumer expectations, and the future of the food landscape. Here…
-
What’s the Deal with GLP-1 Microdosing?
Is Less Really More? When it comes to GLP-1 medications like Ozempic and Wegovy, that’s the question more providers and patients are starting to ask. Originally approved for type 2 diabetes and later for obesity treatment, GLP-1 and other incretin-based therapies have rapidly gained traction in both clinical and consumer spaces. If you’re newer to prescribing or supporting GLP-1 therapy, I’ve put together a four-part series covering key considerations, including initiation, weight management, cost, and side effect mitigation. Now, a new conversation is emerging: GLP-1 microdosing. What does microdosing mean in this context? Does it have clinical merit? And who…
-
ADA Scientific Sessions: Expanding the Discussion to Include Weight Bias
This past weekend, I had the pleasure of attending the American Diabetes Association’s 85th Scientific Sessions in Chicago. It was a phenomenal gathering of researchers, clinicians, scientists, and experts in the field of cardiometabolic health. One of the most compelling shifts I observed was the growing emphasis on obesity care and treatment. The Obesity Association, a new division of the American Diabetes Association, recently published the Standards of Care in Overweight and Obesity to guide respectful, evidence-based treatment. These standards highlight weight stigma and bias as critical issues in clinical practice. To support the launch of the standards, a special…
-
Obesity Care vs. Weight Loss: What’s the Difference?
The International Obesity Collaborative, a global alliance of professional organizations focused on improving obesity care, recently released a powerful consensus statement: obesity care and weight loss are not the same. You might be wondering: What’s the difference? Isn’t all obesity care centered around weight loss? And wouldn’t weight loss be appropriate for someone with obesity? The answer may surprise you. Let’s take a closer look at the International Obesity Collaborative’s new consensus statement, what it means for healthcare professionals, and how it could reshape the way we approach obesity treatment in clinical practice.
-
Goodbye BMI? Why Body Composition Is Gaining Ground in Clinics
The rise of incretin-based therapies for obesity care, like Wegovy (semaglutide) and Zepbound (tirzepatide), has brought renewed attention to the risk of muscle atrophy that can accompany rapid weight loss. To better assess changes in skeletal muscle mass, clinicians are turning to body composition assessment tools to track progress over time. However, the ability to measure, interpret, and communicate changes in body composition is a skill most clinicians haven’t been formally trained in, leaving many feeling like it’s not a tool they can confidently use. I want to push back against that assumption and offer some basic principles to help…
-
GLP-1 Success Starts with Dietitian Leadership
It should come as no surprise that a large part of the success with incretin-based therapies— like Ozempic, Wegovy, Mounjaro, and Zepbound—stems from the effective integration of lifestyle modifications, particularly nutrition. This success occurs at both the individual and programmatic levels. But it’s not always for the reasons you might expect. By the time most people begin incretin-based therapy, especially for weight management, they’ve often already tried a range of diets: calorie counting, commercial weight loss programs like Jenny Craig or Weight Watchers, and more. This time, they’re looking for something different—something that addresses the deeper pathophysiology and root causes…
-
Dizziness and Wegovy: What’s the Connection?
I’ve recently had an increasing number of patients report dizziness while taking Wegovy (semaglutide). This has been observed in both newly prescribed patients and those who have been on the medication for over a year. The dizziness appears distinct from more common side effects such as nausea, vomiting, diarrhea, and constipation. It occurs suddenly and unpredictably but is consistently present. What could be causing this dizziness in patients using Wegovy for weight loss? Let’s explore the science to better understand this phenomenon. What is Wegovy? Wegovy is a once weekly prescription medication containing semaglutide, which is used for chronic weight…
